

Rosario Mazzola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3754739/publications.pdf>

Version: 2024-02-01

126
papers

2,321
citations

218677
26
h-index

315739
38
g-index

132
all docs

132
docs citations

132
times ranked

2571
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. <i>British Journal of Cancer</i> , 2017, 116, 1520-1525.	6.4	121
2	Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. <i>Radiation Oncology</i> , 2018, 13, 38.	2.7	117
3	1.5â€‰T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. <i>Radiation Oncology</i> , 2020, 15, 69.	2.7	94
4	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	2.2	69
5	Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 230-236.	1.9	53
6	First experience and clinical results using a new non-coplanar mono-isocenter technique (HyperArcâ„¢) for Linac-based VMAT radiosurgery in brain metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 193-200.	2.5	50
7	Radiotherapy in patients with connective tissue diseases. <i>Lancet Oncology</i> , The, 2016, 17, e109-e117.	10.7	42
8	Extreme hypofractionation for early prostate cancer: Biology meets technology. <i>Cancer Treatment Reviews</i> , 2016, 50, 48-60.	7.7	40
9	Linac-based radiosurgery for multiple brain metastases: Comparison between two mono-isocenter techniques with multiple non-coplanar arcs. <i>Radiotherapy and Oncology</i> , 2019, 132, 70-78.	0.6	40
10	Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. <i>British Journal of Radiology</i> , 2015, 88, 20140736.	2.2	38
11	Spinal metastases: Is stereotactic body radiation therapy supported by evidences?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 147-158.	4.4	37
12	Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e667-e673.	1.9	35
13	Modern radiotherapy in cancer treatment during pregnancy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 13-19.	4.4	33
14	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 310-315.	1.9	32
15	Phase III study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 113-120.	2.0	32
16	Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. <i>Cancer Treatment Reviews</i> , 2015, 41, 511-518.	7.7	31
17	A comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 877-889.	2.0	31
18	Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 102-111.	4.4	31

#	ARTICLE	IF	CITATIONS
19	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	2.7	31
20	Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Acta Oncologica, 2021, 60, 215-221.	1.8	31
21	Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. Clinical Nuclear Medicine, 2015, 40, e496-e500.	1.3	30
22	Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. Clinical and Translational Oncology, 2017, 19, 189-196.	2.4	30
23	Synchronous bilateral breast cancer irradiation: clinical and dosimetric issues using volumetric modulated arc therapy and simultaneous integrated boost. Radiologia Medica, 2017, 122, 464-471.	7.7	30
24	Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Strahlentherapie Und Onkologie, 2018, 194, 835-842.	2.0	30
25	Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5T MR-guided stereotactic body radiotherapy. Radiation Oncology, 2020, 15, 178.	2.7	30
26	Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2015, 19, 289-294.	1.4	29
27	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlentherapie Und Onkologie, 2020, 196, 213-221.	2.0	29
28	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Medical Oncology, 2018, 35, 121.	2.5	28
29	Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases. Frontiers in Oncology, 2019, 9, 206.	2.8	28
30	A comparative analysis between radiation dose intensification and conventional fractionation in neoadjuvant locally advanced rectal cancer: a monocentric prospective observational study. Radiologia Medica, 2020, 125, 990-998.	7.7	28
31	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	2.2	28
32	Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. Expert Review of Anticancer Therapy, 2016, 16, 731-740.	2.4	27
33	Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients. Strahlentherapie Und Onkologie, 2019, 195, 218-225.	2.0	27
34	Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. Critical Reviews in Oncology/Hematology, 2016, 103, 49-61.	4.4	26
35	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose-volume analysis. Head and Neck, 2016, 38, E815-9.	2.0	26
36	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2547-2554.	2.5	26

#	ARTICLE	IF	CITATIONS
37	Radiomic analysis to predict local response in locally advanced pancreatic cancer treated with stereotactic body radiation therapy. <i>Radiologia Medica</i> , 2022, 127, 100-107.	7.7	26
38	Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. <i>Radiologia Medica</i> , 2016, 121, 60-69.	7.7	25
39	Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. <i>Journal of Geriatric Oncology</i> , 2020, 11, 475-481.	1.0	25
40	Feasibility and safety of 1.5ÂT MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2379-2397.	2.5	25
41	Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. <i>Radiologia Medica</i> , 2019, 124, 309-314.	7.7	23
42	Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. <i>Radiologia Medica</i> , 2018, 123, 719-725.	7.7	22
43	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc®, [®]) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 77-83.	3.3	22
44	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 813-820.	2.0	22
45	An update on radiation therapy in head and neck cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 359-364.	2.4	21
46	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2351-2358.	2.5	21
47	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. <i>Cancers</i> , 2021, 13, 1791.	3.7	21
48	Three-dimensional conformal versus intensity modulated radiotherapy in breast cancer treatment: is necessary a medical reversal?. <i>Radiologia Medica</i> , 2017, 122, 146-153.	7.7	19
49	(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 194-200.	1.4	19
50	New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?. <i>Translational Andrology and Urology</i> , 2019, 8, S538-S541.	1.4	19
51	Adaptive SBRT by 1.5ÂT MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. <i>Physica Medica</i> , 2020, 80, 34-41.	0.7	19
52	Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5ÂT MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes. <i>Radiologia Medica</i> , 2021, 126, 989-997.	7.7	19
53	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 533-538.	2.9	18
54	Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience. <i>Radiologia Medica</i> , 2015, 120, 753-758.	7.7	17

#	ARTICLE	IF	CITATIONS
55	Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. Radiologia Medica, 2017, 122, 676-682.	7.7	17
56	Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. Radiologia Medica, 2018, 123, 406-414.	7.7	17
57	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. Radiation Oncology, 2019, 14, 184.	2.7	17
58	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. Journal of Thoracic Oncology, 2017, 12, 547-555.	1.1	16
59	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiologia Medica, 2017, 122, 952-959.	7.7	16
60	Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by ¹⁸ F-FDG-PET/CT. British Journal of Radiology, 2018, 91, 20180058.	2.2	16
61	Automated Planning for Prostate Stereotactic Body Radiation Therapy on the 1.5 T MR-Linac. Advances in Radiation Oncology, 2022, 7, 100865.	1.2	16
62	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. British Journal of Radiology, 2016, 89, 20160146.	2.2	15
63	What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria. Critical Reviews in Oncology/Hematology, 2017, 111, 20-30.	4.4	15
64	Radiotherapy in patients with HIV: current issues and review of the literature. Lancet Oncology, The, 2017, 18, e379-e393.	10.7	15
65	Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 628-636.	2.0	15
66	Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option?. Radiologia Medica, 2021, 126, 155-162.	7.7	15
67	Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3269-3277.	2.5	15
68	Personalized "Not Omitted" Radiation Oncology for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 4313-4314.	1.6	14
69	Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria. Tumori, 2018, 104, 148-156.	1.1	14
70	Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach. Strahlentherapie Und Onkologie, 2019, 195, 719-724.	2.0	14
71	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Critical Reviews in Oncology/Hematology, 2017, 117, 48-56.	4.4	12
72	Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. Critical Reviews in Oncology/Hematology, 2017, 112, 67-71.	4.4	11

#	ARTICLE	IF	CITATIONS
73	Prostate re-irradiation: current concerns and future perspectives. Expert Review of Anticancer Therapy, 2020, 20, 947-956.	2.4	11
74	Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales. Radiologia Medica, 2015, 120, 1170-1176.	7.7	10
75	Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. Clinical and Translational Oncology, 2017, 19, 593-598.	2.4	10
76	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf . Reviews in Oncology/Hematology, 2019, 134, 104-119.	4.4	10
77	Letter. Neurosurgery, 2015, 77, E310.	1.1	9
78	Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1139-1140.	2.5	9
79	Dosimetrics of intracranial stereotactic radiosurgery. Strahlentherapie Und Onkologie, 2015, 191, 810-811.	2.0	9
80	Volumetric-modulated arc therapy with vaginal cuff simultaneous integrated boost as an alternative to brachytherapy in adjuvant irradiation for endometrial cancer: a prospective study. Anticancer Research, 2015, 35, 2149-55.	1.1	9
81	Low-Dose Bath with Volumetric Modulated arc Therapy in Breast Cancer: “Much ado about Nothing”? Tumori, 2016, 102, 335-336.	1.1	8
82	Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study. Physica Medica, 2018, 49, 135-138.	0.7	8
83	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	1.1	8
84	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiologia Medica, 2020, 125, 491-499.	7.7	8
85	SBRT for elderly oligometastatic patients as a feasible, safe and effective treatment opportunity. Clinical and Experimental Metastasis, 2021, 38, 475-481.	3.3	8
86	Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer. Tumori, 2018, 104, 423-428.	1.1	7
87	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf . Reviews in Oncology/Hematology, 2019, 134, 87-103.	4.4	7
88	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	2.5	6
89	Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system. Radiation Oncology, 2021, 16, 197.	2.7	6
90	Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. Radiologia Medica, 2021, , 1.	7.7	6

#	ARTICLE	IF	CITATIONS
91	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2940-2941.	1.6	5
92	Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1773-1779.	2.5	5
93	Consolidative local therapy in oligometastatic patients. <i>Lancet Oncology</i> , The, 2017, 18, e60.	10.7	4
94	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. <i>British Journal of Radiology</i> , 2019, 92, 20181026.	2.2	4
95	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. <i>Lung Cancer</i> , 2020, 146, 263-275.	2.0	4
96	Mammary Chain Irradiation in Left-Sided Breast Cancer: Can We Reduce the Risk of Secondary Cancer and Ischaemic Heart Disease with Modern Intensity-Modulated Radiotherapy Techniques?. <i>Breast Care</i> , 2021, 16, 358-367.	1.4	4
97	The role of radiotherapy in patients with solid tumours after solid organ transplantation: a systematic review. <i>Lancet Oncology</i> , The, 2021, 22, e93-e104.	10.7	4
98	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. <i>Medical Oncology</i> , 2021, 38, 48.	2.5	4
99	PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 443.	3.3	4
100	Nasal Cavity Reirradiation: A Challenging Case for Comparison between Proton Therapy and Volumetric Modulated arc Therapy. <i>Tumori</i> , 2016, 102, S12-S15.	1.1	3
101	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. <i>Tumori</i> , 2021, 107, 030089162092942.	1.1	3
102	Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5â€‰T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2021, 94, 20210521.	2.2	3
103	Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. <i>Radiologia Medica</i> , 2022, , 1.	7.7	3
104	Stereotactic body radiotherapy for pulmonary oligometastases: aâ€‰monoinstitutional analysis of clinical outcomes and potential prognostic factors. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 934-939.	2.0	3
105	In Regard to Boero etâ€‰al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 855-856.	0.8	2
106	Re: Patrick C. Walsh, Nathan Lawrentschuk. Immediate Adjuvant Radiation Therapy Following Radical Prostatectomy Should Not Be Advised for Men with Extraprostatic Extension Who Have Negative Surgical Margins. <i>Eur Urol</i> 2016;69:191â€‰â€“2. <i>European Urology</i> , 2016, 70, e160-e161.	1.9	2
107	A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice. <i>Journal of Clinical Oncology</i> , 2016, 34, 1963-1964.	1.6	2
108	Sequential Boost in Neoadjuvant Irradiation for T3N0-1 Rectal Cancer: Long-Term Results from a Single-Center Experience. <i>Tumori</i> , 2016, 102, 316-322.	1.1	2

#	ARTICLE	IF	CITATIONS
109	Cachexia in Radiotherapy-Treated Patients With Head and Neck Cancer. JAMA Oncology, 2016, 2, 831.	7.1	2
110	Re: Giorgio Gandaglia, Alberto Briganti, Noel Clarke, et al. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.01.039 . European Urology, 2017, 72, e39-e40.	1.9	2
111	Surprising Complete Response of Intramedullary Spinal Cord Metastasis from Breast Cancer: A Case Report and Literature Review. Tumori, 2017, 103, S28-S30.	1.1	2
112	Patient-Reported Outcomes After Swallowing (SWOARs)-Sparing IMRT in Head and Neck Cancers: Primary Results from a Prospective Study Endorsed by the Head and Neck Study Group (HNSG) of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Dysphagia, 2023, 38, 159-170.	1.8	2
113	In Regard to Arvola et al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 217-218.	0.8	1
114	Watch-and-wait versus surgical resection for patients with rectal cancer. Lancet Oncology, The, 2016, 17, e133-e134.	10.7	1
115	In reply to Simcock et al.. Clinical and Translational Radiation Oncology, 2020, 23, 65.	1.7	1
116	The use of SBRT in the management of oligometastatic gynecological cancer: report of promising results in terms of tolerability and clinical outcomes. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3613-3618.	2.5	1
117	Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: a case report. Tumori, 2011, 97, 115-8.	1.1	1
118	In Regard to Chung et al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 941-942.	0.8	0
119	Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37-43. European Urology, 2017, 71, e121-e122.	1.9	0
120	From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?. Expert Review of Anticancer Therapy, 2017, 17, 157-165.	2.4	0
121	Stereotactic precision and conventional radiotherapy evaluation (SPACE)-Trial for medically inoperable Stage I NSCLC: A lost opportunity?. Radiotherapy and Oncology, 2017, 122, 319.	0.6	0
122	Induction chemotherapy for nasopharyngeal cancer: An eternally unfinished issue?. European Journal of Cancer, 2017, 82, 153-154.	2.8	0
123	Reply to "Comment on "Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study". British Journal of Cancer, 2018, 118, e2-e2.	6.4	0
124	Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma. Lancet Oncology, The, 2019, 20, e611.	10.7	0
125	Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?. Translational Cancer Research, 2016, 5, S405-S407.	1.0	0
126	Using Imaging to Design Dose Volume Constraints for Target and Normal Tissue to Reduce Toxicity. , 2019, , 75-83.		0